Laura Spring, MD, discusses next steps of the phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.
Laura Spring, MD, attending physician, Medical Oncology, Massachusetts General Hospital, instructor of medicine, Harvard Medical School, discusses next steps of the phase 1/2 AMEERA-1 trial (NCT03284957) in estrogen receptor (ER)–positive, HER2-negative advanced breast cancer.
The AMEERA-1 trial is evaluating the novel, oral selective ER degrader (SERD) amcenestrant as a single agent and in combination with other anti-cancer therapies, such as the CDK4/6 inhibitor palbociclib (Ibrance) in postmenopausal women with ER-positive/HER2-negative advanced breast cancer, Spring says. Updated results from the study demonstrated encouraging efficacy with the combination regimen in this patient population.
Looking to the future, further enrollment and follow-up data of the AMEERA-1 trial and other studies evaluating combinations with oral SERDs are needed, Spring says. Although options with oral SERDs will be valuable additions to the ER-positive, HER2-negative paradigm, it is unknown where these agents will fit in. However, these agents appear to yield increased efficacy in patients who harbor ESR1 mutations.
Additionally, it is necessary to evaluate whether these agents have utility in the adjuvant setting to reduce the onset of endocrine resistance and recurrences, Spring concludes.